Skip to main content
main-content
Erschienen in: Die Radiologie 5/2019

08.04.2019 | Leitthema

Gadoliniumablagerungen – Morbus Gadolinium

verfasst von: P. Raczeck, P. Fries, A. Bücker, G. Schneider

Erschienen in: Die Radiologie | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Gadolinium(Gd)-haltige Kontrastmittel (KM) werden seit 1988 in der klinischen MRT-Routinediagnostik weltweit eingesetzt. Dabei wurden alle in der Routine verwendeten Kontrastmittel in der zugelassenen Dosierung hinsichtlich Verträglichkeit, Nebenwirkungsprofil und diagnostischer Wirksamkeit lange Zeit als sicher eingestuft. Mit der Beobachtung der nephrogenen systemischen Fibrose (NSF) und der Gd-Retention im Gehirn änderte sich diese Ansicht jedoch und führte in Europa zum Entzug bzw. zur Einschränkung der Zulassung linearer Gd-Chelate. Insbesondere die NSF sowie die akute Unverträglichkeitsreaktion sind bei der Betrachtung Gd-haltiger Kontrastmittel von primärer klinischer Relevanz. Die schon seit Langem in der Literatur beschriebenen Ablagerungen von gadoliniumhaltigen Strukturen bzw. Strukturkomplexen im Körper wurden in den letzten Jahren insbesondere durch Veröffentlichungen von Ablagerungen im Gehirn sowie auch im Knochenmark wieder in den Vordergrund gerückt, jedoch wurde bisher keine klinische Beschwerdesymptomatik und keine nachhaltige Konsequenz für die Gesundheit der Patienten hierdurch beobachtet. Als Morbus Gadolinium wird ein von überwiegend online aktiven Patienten(interessens)gruppen gebildeter, wissenschaftlich nicht sicher belegter Symptomkomplex beschrieben, der sich nach Anwendung von gadoliniumhaltigen Kontrastmitteln mit großem Beschwerdespektrum offenbart. Die Betroffenen sind von teils chronisch persistierenden, teils remittierenden, und nicht durch andere (Vor‑)Erkrankungen zu erklärenden Beschwerden geplagt.
Literatur
1.
Zurück zum Zitat Hao D, Ai T, Goerner F, Hu X, Runge VM, Tweedle M (2012) MRI contrast agents: basic chemistry and safety. J Magn Reson Imaging 36(5):1060–1071 PubMedCrossRef Hao D, Ai T, Goerner F, Hu X, Runge VM, Tweedle M (2012) MRI contrast agents: basic chemistry and safety. J Magn Reson Imaging 36(5):1060–1071 PubMedCrossRef
2.
Zurück zum Zitat Bleicher AG, Kanal E (2008) Assessment of adverse reaction rates to a newly approved MRI contrast agent: review of 23,553 administrations of gadobenate dimeglumine. Ajr Am J Roentgenol 191(6):W307–W311 PubMedCrossRef Bleicher AG, Kanal E (2008) Assessment of adverse reaction rates to a newly approved MRI contrast agent: review of 23,553 administrations of gadobenate dimeglumine. Ajr Am J Roentgenol 191(6):W307–W311 PubMedCrossRef
3.
4.
Zurück zum Zitat Kanal E, Tweedle MF (2015) Residual or retained gadolinium: practical implications for radiologists and our patients. Radiology 275(3):630–634 PubMedCrossRef Kanal E, Tweedle MF (2015) Residual or retained gadolinium: practical implications for radiologists and our patients. Radiology 275(3):630–634 PubMedCrossRef
5.
Zurück zum Zitat Grobner T (2006) Gadolinium—a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21(4):1104–1108 PubMedCrossRef Grobner T (2006) Gadolinium—a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21(4):1104–1108 PubMedCrossRef
6.
Zurück zum Zitat Marckmann P, Skov L, Rossen K, Dupont A, Damholt MB, Heaf JG, Thomsen HS (2006) Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17(9):2359–2362 PubMedCrossRef Marckmann P, Skov L, Rossen K, Dupont A, Damholt MB, Heaf JG, Thomsen HS (2006) Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17(9):2359–2362 PubMedCrossRef
7.
Zurück zum Zitat Hope TA, High WA, Leboit PE, Chaopathomkul B, Rogut VS, Herfkens RJ, Brasch RC (2009) Nephrogenic systemic fibrosis in rats treated with erythropoietin and intravenous iron. Radiology 253(2):390–398 PubMedCrossRef Hope TA, High WA, Leboit PE, Chaopathomkul B, Rogut VS, Herfkens RJ, Brasch RC (2009) Nephrogenic systemic fibrosis in rats treated with erythropoietin and intravenous iron. Radiology 253(2):390–398 PubMedCrossRef
8.
Zurück zum Zitat Wertman R, Altun E, Martin DR, Mitchell DG, Leyendecker JR, O’Malley RB, Parsons DJ, Fuller ER III, Semelka RC (2008) Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast agents at four American universities. Radiology 248(3):799–806 PubMedCrossRef Wertman R, Altun E, Martin DR, Mitchell DG, Leyendecker JR, O’Malley RB, Parsons DJ, Fuller ER III, Semelka RC (2008) Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast agents at four American universities. Radiology 248(3):799–806 PubMedCrossRef
9.
Zurück zum Zitat Fretellier N, Idee JM, Guerret S, Hollenbeck C, Hartmann D, Gonzalez W, Robic C, Port M, Corot C (2011) Clinical, biological, and skin histopathologic effects of ionic macrocyclic and nonionic linear gadolinium chelates in a rat model of nephrogenic systemic fibrosis. Invest Radiol 46(2):85–93 PubMedCrossRef Fretellier N, Idee JM, Guerret S, Hollenbeck C, Hartmann D, Gonzalez W, Robic C, Port M, Corot C (2011) Clinical, biological, and skin histopathologic effects of ionic macrocyclic and nonionic linear gadolinium chelates in a rat model of nephrogenic systemic fibrosis. Invest Radiol 46(2):85–93 PubMedCrossRef
10.
Zurück zum Zitat Abujudeh HH, Kaewlai R, Kagan A, Chibnik LB, Nazarian RM, High WA, Kay J (2009) Nephrogenic systemic fibrosis after gadopentetate dimeglumine exposure: case series of 36 patients. Radiology 253(1):81–89 PubMedCrossRef Abujudeh HH, Kaewlai R, Kagan A, Chibnik LB, Nazarian RM, High WA, Kay J (2009) Nephrogenic systemic fibrosis after gadopentetate dimeglumine exposure: case series of 36 patients. Radiology 253(1):81–89 PubMedCrossRef
11.
Zurück zum Zitat Altun E, Martin DR, Wertman R, Lugo-Somolinos A, Fuller ER III, Semelka RC (2009) Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy—report from two U.S. universities. Radiology 253(3):689–696 PubMedCrossRef Altun E, Martin DR, Wertman R, Lugo-Somolinos A, Fuller ER III, Semelka RC (2009) Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy—report from two U.S. universities. Radiology 253(3):689–696 PubMedCrossRef
12.
Zurück zum Zitat Kanda T, Ishii K, Kawaguchi H, Kitajima K, Takenaka D (2014) High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology 270(3):834–841 PubMedCrossRef Kanda T, Ishii K, Kawaguchi H, Kitajima K, Takenaka D (2014) High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology 270(3):834–841 PubMedCrossRef
13.
Zurück zum Zitat Murata N, Gonzalez-Cuyar LF, Murata K, Fligner C, Dills R, Hippe D, Maravilla KR (2016) Macrocyclic and other non-group 1 gadolinium contrast agents deposit low levels of gadolinium in brain and Bone tissue: preliminary results from 9 patients with normal renal function. Invest Radiol 51(7):447–453 PubMedCrossRef Murata N, Gonzalez-Cuyar LF, Murata K, Fligner C, Dills R, Hippe D, Maravilla KR (2016) Macrocyclic and other non-group 1 gadolinium contrast agents deposit low levels of gadolinium in brain and Bone tissue: preliminary results from 9 patients with normal renal function. Invest Radiol 51(7):447–453 PubMedCrossRef
14.
Zurück zum Zitat Kanda T, Fukusato T, Matsuda M, Toyoda K, Oba H, Kotoku J, Haruyama T, Kitajima K, Furui S (2015) Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy. Radiology 276(1):228–232 PubMedCrossRef Kanda T, Fukusato T, Matsuda M, Toyoda K, Oba H, Kotoku J, Haruyama T, Kitajima K, Furui S (2015) Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy. Radiology 276(1):228–232 PubMedCrossRef
15.
Zurück zum Zitat McDonald RJ, McDonald JS, Kallmes DF, Jentoft ME, Murray DL, Thielen KR, Williamson EE, Eckel LJ (2015) Intracranial gadolinium deposition after contrast-enhanced MR imaging. Radiology 275(3):772–782 PubMedCrossRef McDonald RJ, McDonald JS, Kallmes DF, Jentoft ME, Murray DL, Thielen KR, Williamson EE, Eckel LJ (2015) Intracranial gadolinium deposition after contrast-enhanced MR imaging. Radiology 275(3):772–782 PubMedCrossRef
16.
Zurück zum Zitat Joffe P, Thomsen HS, Meusel M (1998) Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol 5(7):491–502 PubMedCrossRef Joffe P, Thomsen HS, Meusel M (1998) Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol 5(7):491–502 PubMedCrossRef
17.
Zurück zum Zitat Gibby WA, Gibby KA, Gibby WA (2004) Comparison of Gd DTPA-BMA (Omniscan) versus Gd HP-DO3A (ProHance) retention in human bone tissue by inductively coupled plasma atomic emission spectroscopy. Invest Radiol 39(3):138–142 PubMedCrossRef Gibby WA, Gibby KA, Gibby WA (2004) Comparison of Gd DTPA-BMA (Omniscan) versus Gd HP-DO3A (ProHance) retention in human bone tissue by inductively coupled plasma atomic emission spectroscopy. Invest Radiol 39(3):138–142 PubMedCrossRef
18.
Zurück zum Zitat Darrah TH, Prutsman-Pfeiffer JJ, Poreda RJ, Ellen CM, Hauschka PV, Hannigan RE (2009) Incorporation of excess gadolinium into human bone from medical contrast agents. Metallomics 1(6):479–488 PubMedCrossRef Darrah TH, Prutsman-Pfeiffer JJ, Poreda RJ, Ellen CM, Hauschka PV, Hannigan RE (2009) Incorporation of excess gadolinium into human bone from medical contrast agents. Metallomics 1(6):479–488 PubMedCrossRef
19.
Zurück zum Zitat Runge VM (2000) Safety of approved MR contrast media for intravenous injection. J Magn Reson Imaging 12(2):205–213 PubMedCrossRef Runge VM (2000) Safety of approved MR contrast media for intravenous injection. J Magn Reson Imaging 12(2):205–213 PubMedCrossRef
20.
Zurück zum Zitat Weiss KL (1990) Severe anaphylactoid reaction after i.v. Gd-DTPA. Magn Reson Imaging 8(6):817–818 PubMedCrossRef Weiss KL (1990) Severe anaphylactoid reaction after i.v. Gd-DTPA. Magn Reson Imaging 8(6):817–818 PubMedCrossRef
21.
Zurück zum Zitat Beaudouin E, Kanny G, Blanloeil Y, Guilloux L, Renaudin JM, Moneret-Vautrin DA (2003) Anaphylactic shock induced by gadoterate meglumine (DOTAREM). Eur Ann Allergy Clin Immunol 35(10):382–385 PubMed Beaudouin E, Kanny G, Blanloeil Y, Guilloux L, Renaudin JM, Moneret-Vautrin DA (2003) Anaphylactic shock induced by gadoterate meglumine (DOTAREM). Eur Ann Allergy Clin Immunol 35(10):382–385 PubMed
22.
Zurück zum Zitat Runge VM (2001) Safety of magnetic resonance contrast media. Top Magn Reson Imaging 12(4):309–314 PubMedCrossRef Runge VM (2001) Safety of magnetic resonance contrast media. Top Magn Reson Imaging 12(4):309–314 PubMedCrossRef
23.
Zurück zum Zitat Ansell G, Tweedie MC, West CR, Evans P, Couch L (1980) The current status of reactions to intravenous contrast media. Invest Radiol 15(6 Suppl):32–39 CrossRef Ansell G, Tweedie MC, West CR, Evans P, Couch L (1980) The current status of reactions to intravenous contrast media. Invest Radiol 15(6 Suppl):32–39 CrossRef
24.
Zurück zum Zitat Jung JW, Kang HR, Kim MH, Lee W, Min KU, Han MH, Cho SH (2012) Immediate hypersensitivity reaction to gadolinium-based MR contrast media. Radiology 264(2):414–422 PubMedCrossRef Jung JW, Kang HR, Kim MH, Lee W, Min KU, Han MH, Cho SH (2012) Immediate hypersensitivity reaction to gadolinium-based MR contrast media. Radiology 264(2):414–422 PubMedCrossRef
25.
Zurück zum Zitat Kanal E, Maravilla K, Rowley HA (2014) Gadolinium contrast agents for CNS imaging: current concepts and clinical evidence. Ajnr Am J Neuroradiol 35(12):2215–2226 PubMedCrossRefPubMedCentral Kanal E, Maravilla K, Rowley HA (2014) Gadolinium contrast agents for CNS imaging: current concepts and clinical evidence. Ajnr Am J Neuroradiol 35(12):2215–2226 PubMedCrossRefPubMedCentral
26.
Zurück zum Zitat Semelka RC, Ramalho M, AlObaidy M, Ramalho J (2016) Gadolinium in humans: a family of disorders. Ajr Am J Roentgenol 207(2):229–233 PubMedCrossRef Semelka RC, Ramalho M, AlObaidy M, Ramalho J (2016) Gadolinium in humans: a family of disorders. Ajr Am J Roentgenol 207(2):229–233 PubMedCrossRef
27.
Zurück zum Zitat ESUR Contrast Media Safety Committee (2018) ESUR Contrast Media guidelines version 10.0 ESUR Contrast Media Safety Committee (2018) ESUR Contrast Media guidelines version 10.0
28.
Zurück zum Zitat American College of Radiology (ACR), Committee on Drugs and Contrast Media (2017) ACR manual on contrast media. American College of Radiology, (version 10.3) American College of Radiology (ACR), Committee on Drugs and Contrast Media (2017) ACR manual on contrast media. American College of Radiology, (version 10.3)
29.
Zurück zum Zitat Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, Leboit PE (2000) Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 356(9234):1000–1001 PubMedCrossRef Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, Leboit PE (2000) Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 356(9234):1000–1001 PubMedCrossRef
30.
Zurück zum Zitat Broome DR (2008) Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting. Eur J Radiol 66(2):230–234 PubMedCrossRef Broome DR (2008) Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting. Eur J Radiol 66(2):230–234 PubMedCrossRef
31.
Zurück zum Zitat Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA (2007) Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. Ajr Am J Roentgenol 188(2):586–592 PubMedCrossRef Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA (2007) Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. Ajr Am J Roentgenol 188(2):586–592 PubMedCrossRef
32.
Zurück zum Zitat Sadowski EA, Bennett LK, Chan MR, Wentland AL, Garrett AL, Garrett RW, Djamali A (2007) Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 243(1):148–157 PubMedCrossRef Sadowski EA, Bennett LK, Chan MR, Wentland AL, Garrett AL, Garrett RW, Djamali A (2007) Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 243(1):148–157 PubMedCrossRef
33.
Zurück zum Zitat Shabana WM, Cohan RH, Ellis JH, Hussain HK, Francis IR, Su LD, Mukherji SK, Swartz RD (2008) Nephrogenic systemic fibrosis: a report of 29 cases. Ajr Am J Roentgenol 190(3):736–741 PubMedCrossRef Shabana WM, Cohan RH, Ellis JH, Hussain HK, Francis IR, Su LD, Mukherji SK, Swartz RD (2008) Nephrogenic systemic fibrosis: a report of 29 cases. Ajr Am J Roentgenol 190(3):736–741 PubMedCrossRef
34.
Zurück zum Zitat Kallen AJ, Jhung MA, Cheng S, Hess T, Turabelidze G, Abramova L, Arduino M, Guarner J, Pollack B, Saab G, Patel PR (2008) Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study. Am J Kidney Dis 51(6):966–975 PubMedCrossRef Kallen AJ, Jhung MA, Cheng S, Hess T, Turabelidze G, Abramova L, Arduino M, Guarner J, Pollack B, Saab G, Patel PR (2008) Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study. Am J Kidney Dis 51(6):966–975 PubMedCrossRef
35.
Zurück zum Zitat Nandwana SB, Moreno CC, Osipow MT, Sekhar A, Cox KL (2015) Gadobenate Dimeglumine administration and Nephrogenic systemic fibrosis: is there a real risk in patients with impaired renal function? Radiology 276(3):741–747 PubMedCrossRef Nandwana SB, Moreno CC, Osipow MT, Sekhar A, Cox KL (2015) Gadobenate Dimeglumine administration and Nephrogenic systemic fibrosis: is there a real risk in patients with impaired renal function? Radiology 276(3):741–747 PubMedCrossRef
36.
Zurück zum Zitat Abraham JL, Thakral C, Skov L, Rossen K, Marckmann P (2008) Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis. Br J Dermatol 158(2):273–280 PubMedCrossRef Abraham JL, Thakral C, Skov L, Rossen K, Marckmann P (2008) Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis. Br J Dermatol 158(2):273–280 PubMedCrossRef
37.
Zurück zum Zitat Collidge TA, Thomson PC, Mark PB, Traynor JP, Jardine AG, Morris ST, Simpson K, Roditi GH (2007) Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Radiology 245(1):168–175 PubMedCrossRef Collidge TA, Thomson PC, Mark PB, Traynor JP, Jardine AG, Morris ST, Simpson K, Roditi GH (2007) Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Radiology 245(1):168–175 PubMedCrossRef
38.
Zurück zum Zitat Rosenkranz AR, Grobner T, Mayer GJ (2007) Conventional or Gadolinium containing contrast media: the choice between acute renal failure or Nephrogenic Systemic Fibrosis? Wien Klin Wochenschr 119(9–10):271–275 PubMedCrossRef Rosenkranz AR, Grobner T, Mayer GJ (2007) Conventional or Gadolinium containing contrast media: the choice between acute renal failure or Nephrogenic Systemic Fibrosis? Wien Klin Wochenschr 119(9–10):271–275 PubMedCrossRef
39.
Zurück zum Zitat Sanyal S, Marckmann P, Scherer S, Abraham JL (2011) Multiorgan gadolinium (Gd) deposition and fibrosis in a patient with nephrogenic systemic fibrosis—an autopsy-based review. Nephrol Dial Transplant 26(11):3616–3626 PubMedCrossRef Sanyal S, Marckmann P, Scherer S, Abraham JL (2011) Multiorgan gadolinium (Gd) deposition and fibrosis in a patient with nephrogenic systemic fibrosis—an autopsy-based review. Nephrol Dial Transplant 26(11):3616–3626 PubMedCrossRef
40.
Zurück zum Zitat Christensen KN, Lee CU, Hanley MM, Leung N, Moyer TP, Pittelkow MR (2011) Quantification of gadolinium in fresh skin and serum samples from patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 64(1):91–96 PubMedCrossRef Christensen KN, Lee CU, Hanley MM, Leung N, Moyer TP, Pittelkow MR (2011) Quantification of gadolinium in fresh skin and serum samples from patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 64(1):91–96 PubMedCrossRef
41.
Zurück zum Zitat Rocklage SM, Worah D, Kim SH (1991) Metal ion release from paramagnetic chelates: what is tolerable? Magn Reson Med 22(2):216–221 PubMedCrossRef Rocklage SM, Worah D, Kim SH (1991) Metal ion release from paramagnetic chelates: what is tolerable? Magn Reson Med 22(2):216–221 PubMedCrossRef
42.
Zurück zum Zitat Tweedle MF (1992) Physicochemical properties of gadoteridol and other magnetic resonance contrast agents. Invest Radiol 27(Suppl 1):2–6 Tweedle MF (1992) Physicochemical properties of gadoteridol and other magnetic resonance contrast agents. Invest Radiol 27(Suppl 1):2–6
43.
Zurück zum Zitat Xia D, Davis RL, Crawford JA, Abraham JL (2010) Gadolinium released from MR contrast agents is deposited in brain tumors: in situ demonstration using scanning electron microscopy with energy dispersive X‑ray spectroscopy. Acta Radiol 51(10):1126–1136 PubMedCrossRef Xia D, Davis RL, Crawford JA, Abraham JL (2010) Gadolinium released from MR contrast agents is deposited in brain tumors: in situ demonstration using scanning electron microscopy with energy dispersive X‑ray spectroscopy. Acta Radiol 51(10):1126–1136 PubMedCrossRef
44.
Zurück zum Zitat Errante Y, Cirimele V, Mallio CA, Di L. V, Zobel BB, Quattrocchi CC (2014) Progressive increase of T1 signal intensity of the dentate nucleus on unenhanced magnetic resonance images is associated with cumulative doses of intravenously administered gadodiamide in patients with normal renal function, suggesting dechelation. Invest Radiol 49(10):685–690 PubMedCrossRef Errante Y, Cirimele V, Mallio CA, Di L. V, Zobel BB, Quattrocchi CC (2014) Progressive increase of T1 signal intensity of the dentate nucleus on unenhanced magnetic resonance images is associated with cumulative doses of intravenously administered gadodiamide in patients with normal renal function, suggesting dechelation. Invest Radiol 49(10):685–690 PubMedCrossRef
45.
Zurück zum Zitat Quattrocchi CC, Mallio CA, Errante Y, Beomonte ZB (2015) High T1 signal intensity in dentate nucleus after multiple injections of linear gadolinium chelates. Radiology 276(2):616–617 PubMedCrossRef Quattrocchi CC, Mallio CA, Errante Y, Beomonte ZB (2015) High T1 signal intensity in dentate nucleus after multiple injections of linear gadolinium chelates. Radiology 276(2):616–617 PubMedCrossRef
46.
Zurück zum Zitat Quattrocchi CC, Mallio CA, Errante Y, Cirimele V, Carideo L, Ax A, Zobel BB (2015) Gadodiamide and dentate nucleus T1 Hyperintensity in patients with Meningioma evaluated by multiple follow-up contrast-enhanced magnetic resonance examinations with no systemic interval therapy. Invest Radiol 50(7):470–472 PubMedCrossRef Quattrocchi CC, Mallio CA, Errante Y, Cirimele V, Carideo L, Ax A, Zobel BB (2015) Gadodiamide and dentate nucleus T1 Hyperintensity in patients with Meningioma evaluated by multiple follow-up contrast-enhanced magnetic resonance examinations with no systemic interval therapy. Invest Radiol 50(7):470–472 PubMedCrossRef
47.
Zurück zum Zitat Cao Y, Huang DQ, Shih G, Prince MR (2016) Signal change in the dentate nucleus on T1-weighted MR images after multiple administrations of Gadopentetate Dimeglumine versus Gadobutrol. Ajr Am J Roentgenol 206(2):414–419 PubMedCrossRef Cao Y, Huang DQ, Shih G, Prince MR (2016) Signal change in the dentate nucleus on T1-weighted MR images after multiple administrations of Gadopentetate Dimeglumine versus Gadobutrol. Ajr Am J Roentgenol 206(2):414–419 PubMedCrossRef
48.
Zurück zum Zitat Kanda T, Osawa M, Oba H, Toyoda K, Kotoku J, Haruyama T, Takeshita K, Furui S (2015) High signal intensity in dentate nucleus on Unenhanced T1-weighted MR images: association with linear versus Macrocyclic gadolinium chelate administration. Radiology 275(3):803–809 PubMedCrossRef Kanda T, Osawa M, Oba H, Toyoda K, Kotoku J, Haruyama T, Takeshita K, Furui S (2015) High signal intensity in dentate nucleus on Unenhanced T1-weighted MR images: association with linear versus Macrocyclic gadolinium chelate administration. Radiology 275(3):803–809 PubMedCrossRef
49.
Zurück zum Zitat Weberling LD, Kieslich PJ, Kickingereder P, Wick W, Bendszus M, Schlemmer HP, Radbruch A (2015) Increased signal intensity in the dentate nucleus on Unenhanced T1-weighted images after Gadobenate Dimeglumine administration. Invest Radiol 50(11):743–748 PubMedCrossRef Weberling LD, Kieslich PJ, Kickingereder P, Wick W, Bendszus M, Schlemmer HP, Radbruch A (2015) Increased signal intensity in the dentate nucleus on Unenhanced T1-weighted images after Gadobenate Dimeglumine administration. Invest Radiol 50(11):743–748 PubMedCrossRef
50.
Zurück zum Zitat Radbruch A, Weberling LD, Kieslich PJ, Hepp J, Kickingereder P, Wick W, Schlemmer HP, Bendszus M (2015) High-signal intensity in the dentate nucleus and Globus Pallidus on Unenhanced T1-weighted images: evaluation of the Macrocyclic gadolinium-based contrast agent Gadobutrol. Invest Radiol 50(12):805–810 PubMedCrossRef Radbruch A, Weberling LD, Kieslich PJ, Hepp J, Kickingereder P, Wick W, Schlemmer HP, Bendszus M (2015) High-signal intensity in the dentate nucleus and Globus Pallidus on Unenhanced T1-weighted images: evaluation of the Macrocyclic gadolinium-based contrast agent Gadobutrol. Invest Radiol 50(12):805–810 PubMedCrossRef
51.
Zurück zum Zitat Radbruch A, Weberling LD, Kieslich PJ, Hepp J, Kickingereder P, Wick W, Schlemmer HP, Bendszus M (2016) Intraindividual analysis of signal intensity changes in the dentate nucleus after consecutive serial applications of linear and Macrocyclic gadolinium-based contrast agents. Invest Radiol 51(11):683–690 PubMedCrossRef Radbruch A, Weberling LD, Kieslich PJ, Hepp J, Kickingereder P, Wick W, Schlemmer HP, Bendszus M (2016) Intraindividual analysis of signal intensity changes in the dentate nucleus after consecutive serial applications of linear and Macrocyclic gadolinium-based contrast agents. Invest Radiol 51(11):683–690 PubMedCrossRef
52.
Zurück zum Zitat Stojanov DA, Aracki-Trenkic A, Vojinovic S, Benedeto-Stojanov D, Ljubisavljevic S (2016) Increasing signal intensity within the dentate nucleus and globus pallidus on unenhanced T1W magnetic resonance images in patients with relapsing-remitting multiple sclerosis: correlation with cumulative dose of a macrocyclic gadolinium-based contrast agent, gadobutrol. Eur Radiol 26(3):807–815 PubMedCrossRef Stojanov DA, Aracki-Trenkic A, Vojinovic S, Benedeto-Stojanov D, Ljubisavljevic S (2016) Increasing signal intensity within the dentate nucleus and globus pallidus on unenhanced T1W magnetic resonance images in patients with relapsing-remitting multiple sclerosis: correlation with cumulative dose of a macrocyclic gadolinium-based contrast agent, gadobutrol. Eur Radiol 26(3):807–815 PubMedCrossRef
53.
Zurück zum Zitat Schneider GK, Stroeder J, Roditi G, Colosimo C, Armstrong P, Martucci M, Buecker A, Raczeck P (2017) T1 signal measurements in pediatric brain: findings after multiple exposures to Gadobenate Dimeglumine for imaging of Nonneurologic disease. Ajnr Am J Neuroradiol 38(9):1799–1806 PubMedCrossRefPubMedCentral Schneider GK, Stroeder J, Roditi G, Colosimo C, Armstrong P, Martucci M, Buecker A, Raczeck P (2017) T1 signal measurements in pediatric brain: findings after multiple exposures to Gadobenate Dimeglumine for imaging of Nonneurologic disease. Ajnr Am J Neuroradiol 38(9):1799–1806 PubMedCrossRefPubMedCentral
54.
Zurück zum Zitat Bjornerud A, Vatnehol SAS, Larsson C, Due-Tonnessen P, Hol PK, Groote IR (2017) Signal enhancement of the dentate nucleus at Unenhanced MR imaging after very high cumulative doses of the Macrocyclic gadolinium-based contrast agent Gadobutrol: an observational study. Radiology 285(2):434–444 PubMedCrossRef Bjornerud A, Vatnehol SAS, Larsson C, Due-Tonnessen P, Hol PK, Groote IR (2017) Signal enhancement of the dentate nucleus at Unenhanced MR imaging after very high cumulative doses of the Macrocyclic gadolinium-based contrast agent Gadobutrol: an observational study. Radiology 285(2):434–444 PubMedCrossRef
55.
Zurück zum Zitat Ramalho J, Castillo M, AlObaidy M, Nunes RH, Ramalho M, Dale BM, Semelka RC (2015) High signal intensity in Globus Pallidus and dentate nucleus on Unenhanced T1-weighted MR images: evaluation of two linear gadolinium-based contrast agents. Radiology 276(3):836–844 PubMedCrossRef Ramalho J, Castillo M, AlObaidy M, Nunes RH, Ramalho M, Dale BM, Semelka RC (2015) High signal intensity in Globus Pallidus and dentate nucleus on Unenhanced T1-weighted MR images: evaluation of two linear gadolinium-based contrast agents. Radiology 276(3):836–844 PubMedCrossRef
56.
Zurück zum Zitat Dekkers IA, Roos R, van der Molen AJ (2018) Gadolinium retention after administration of contrast agents based on linear chelators and the recommendations of the European Medicines Agency. Eur Radiol 28(4):1579–1584 PubMedCrossRef Dekkers IA, Roos R, van der Molen AJ (2018) Gadolinium retention after administration of contrast agents based on linear chelators and the recommendations of the European Medicines Agency. Eur Radiol 28(4):1579–1584 PubMedCrossRef
57.
Zurück zum Zitat Prosch H, Grois N, Wnorowski M, Steiner M, Prayer D (2007) Long-term MR imaging course of neurodegenerative Langerhans cell histiocytosis. Ajnr Am J Neuroradiol 28(6):1022–1028 PubMedCrossRefPubMedCentral Prosch H, Grois N, Wnorowski M, Steiner M, Prayer D (2007) Long-term MR imaging course of neurodegenerative Langerhans cell histiocytosis. Ajnr Am J Neuroradiol 28(6):1022–1028 PubMedCrossRefPubMedCentral
58.
Zurück zum Zitat Maeda H, Sato M, Yoshikawa A, Kimura M, Sonomura T, Terada M, Kishi K (1997) Brain MR imaging in patients with hepatic cirrhosis: relationship between high intensity signal in basal ganglia on T1-weighted images and elemental concentrations in brain. Neuroradiology 39(8):546–550 PubMedCrossRef Maeda H, Sato M, Yoshikawa A, Kimura M, Sonomura T, Terada M, Kishi K (1997) Brain MR imaging in patients with hepatic cirrhosis: relationship between high intensity signal in basal ganglia on T1-weighted images and elemental concentrations in brain. Neuroradiology 39(8):546–550 PubMedCrossRef
59.
Zurück zum Zitat Mochizuki H, Kamakura K, Masaki T, Okano M, Nagata N, Inui A, Fujisawa T, Kaji T (1997) Atypical MRI features of Wilson’s disease: high signal in globus pallidus on T1-weighted images. Neuroradiology 39(3):171–174 PubMedCrossRef Mochizuki H, Kamakura K, Masaki T, Okano M, Nagata N, Inui A, Fujisawa T, Kaji T (1997) Atypical MRI features of Wilson’s disease: high signal in globus pallidus on T1-weighted images. Neuroradiology 39(3):171–174 PubMedCrossRef
60.
Zurück zum Zitat Frenzel T, Apte C, Jost G, Schockel L, Lohrke J, Pietsch H (2017) Quantification and assessment of the chemical form of residual gadolinium in the brain after repeated administration of gadolinium-based contrast agents: comparative study in rats. Invest Radiol 52(7):396–404 PubMedPubMedCentralCrossRef Frenzel T, Apte C, Jost G, Schockel L, Lohrke J, Pietsch H (2017) Quantification and assessment of the chemical form of residual gadolinium in the brain after repeated administration of gadolinium-based contrast agents: comparative study in rats. Invest Radiol 52(7):396–404 PubMedPubMedCentralCrossRef
61.
Zurück zum Zitat Murata N, Murata K, Gonzalez-Cuyar LF, Maravilla KR (2016) Gadolinium tissue deposition in brain and bone. Magn Reson Imaging 34(10):1359–1365 PubMedCrossRef Murata N, Murata K, Gonzalez-Cuyar LF, Maravilla KR (2016) Gadolinium tissue deposition in brain and bone. Magn Reson Imaging 34(10):1359–1365 PubMedCrossRef
62.
Zurück zum Zitat Maximova N, Gregori M, Zennaro F, Sonzogni A, Simeone R, Zanon D (2016) Hepatic gadolinium deposition and reversibility after contrast agent-enhanced MR imaging of pediatric Hematopoietic stem cell transplant recipients. Radiology 281(2):418–426 PubMedCrossRef Maximova N, Gregori M, Zennaro F, Sonzogni A, Simeone R, Zanon D (2016) Hepatic gadolinium deposition and reversibility after contrast agent-enhanced MR imaging of pediatric Hematopoietic stem cell transplant recipients. Radiology 281(2):418–426 PubMedCrossRef
63.
Zurück zum Zitat European Medicine Agency (2018) EMA’s final opinion confirms restrictions on use of linear gadolinium agents in body scans. https://​www.​ema.​europa.​eu (Erstellt: 23. Nov. 2017). Zugegriffen: 6. Dez. 2018 (EMA/625317/2017) European Medicine Agency (2018) EMA’s final opinion confirms restrictions on use of linear gadolinium agents in body scans. https://​www.​ema.​europa.​eu (Erstellt: 23. Nov. 2017). Zugegriffen: 6. Dez. 2018 (EMA/625317/2017)
64.
Zurück zum Zitat Taoka T, Naganawa S (2018) Gadolinium-based contrast media, cerebrospinal fluid and the Glymphatic system: possible mechanisms for the deposition of gadolinium in the brain. Magn Reson Med Sci 17(2):111–119 PubMedPubMedCentralCrossRef Taoka T, Naganawa S (2018) Gadolinium-based contrast media, cerebrospinal fluid and the Glymphatic system: possible mechanisms for the deposition of gadolinium in the brain. Magn Reson Med Sci 17(2):111–119 PubMedPubMedCentralCrossRef
65.
Zurück zum Zitat Welk B, McArthur E, Morrow SA, MacDonald P, Hayward J, Leung A, Lum A (2016) Association between gadolinium contrast exposure and the risk of parkinsonism. JAMA 316(1):96–98 PubMedCrossRef Welk B, McArthur E, Morrow SA, MacDonald P, Hayward J, Leung A, Lum A (2016) Association between gadolinium contrast exposure and the risk of parkinsonism. JAMA 316(1):96–98 PubMedCrossRef
66.
Zurück zum Zitat Cocozza S, Pontillo G, Lanzillo R, Russo C, Petracca M, Di SM, Paolella C, Vola EA, Criscuolo C, Moccia M, Lamberti A, Monti S, Brescia MV, Elefante A, Palma G, Tedeschi E, Brunetti A (2019) MRI features suggestive of gadolinium retention do not correlate with expanded disability status scale worsening in multiple sclerosis. Neuroradiology 61(2):155–162 PubMedCrossRef Cocozza S, Pontillo G, Lanzillo R, Russo C, Petracca M, Di SM, Paolella C, Vola EA, Criscuolo C, Moccia M, Lamberti A, Monti S, Brescia MV, Elefante A, Palma G, Tedeschi E, Brunetti A (2019) MRI features suggestive of gadolinium retention do not correlate with expanded disability status scale worsening in multiple sclerosis. Neuroradiology 61(2):155–162 PubMedCrossRef
67.
Zurück zum Zitat McDonald RJ, McDonald JS, Kallmes DF, Jentoft ME, Paolini MA, Murray DL, Williamson EE, Eckel LJ (2017) Gadolinium deposition in human brain tissues after contrast-enhanced MR imaging in adult patients without Intracranial abnormalities. Radiology 285(2):546–554 PubMedCrossRef McDonald RJ, McDonald JS, Kallmes DF, Jentoft ME, Paolini MA, Murray DL, Williamson EE, Eckel LJ (2017) Gadolinium deposition in human brain tissues after contrast-enhanced MR imaging in adult patients without Intracranial abnormalities. Radiology 285(2):546–554 PubMedCrossRef
68.
Zurück zum Zitat McDonald RJ, McDonald JS, Dai D, Schroeder D, Jentoft ME, Murray DL, Kadirvel R, Eckel LJ, Kallmes DF (2017) Comparison of gadolinium concentrations within multiple rat organs after intravenous administration of linear versus Macrocyclic gadolinium chelates. Radiology 285(2):536–545 PubMedCrossRef McDonald RJ, McDonald JS, Dai D, Schroeder D, Jentoft ME, Murray DL, Kadirvel R, Eckel LJ, Kallmes DF (2017) Comparison of gadolinium concentrations within multiple rat organs after intravenous administration of linear versus Macrocyclic gadolinium chelates. Radiology 285(2):536–545 PubMedCrossRef
69.
Zurück zum Zitat Forslin Y, Shams S, Hashim F, Aspelin P, Bergendal G, Martola J, Fredrikson S, Kristoffersen-Wiberg M, Granberg T (2017) Retention of gadolinium-based contrast agents in multiple sclerosis: retrospective analysis of an 18-year longitudinal study. Ajnr Am J Neuroradiol 38(7):1311–1316 PubMedCrossRefPubMedCentral Forslin Y, Shams S, Hashim F, Aspelin P, Bergendal G, Martola J, Fredrikson S, Kristoffersen-Wiberg M, Granberg T (2017) Retention of gadolinium-based contrast agents in multiple sclerosis: retrospective analysis of an 18-year longitudinal study. Ajnr Am J Neuroradiol 38(7):1311–1316 PubMedCrossRefPubMedCentral
70.
Zurück zum Zitat Semelka RC, Ramalho J, Vakharia A, AlObaidy M, Burke LM, Jay M, Ramalho M (2016) Gadolinium deposition disease: Initial description of a disease that has been around for a while. Magn Reson Imaging 34(10):1383–1390 PubMedCrossRef Semelka RC, Ramalho J, Vakharia A, AlObaidy M, Burke LM, Jay M, Ramalho M (2016) Gadolinium deposition disease: Initial description of a disease that has been around for a while. Magn Reson Imaging 34(10):1383–1390 PubMedCrossRef
73.
Zurück zum Zitat Gathings RM, Reddy R, Santa CD, Brodell RT (2015) Gadolinium-associated plaques: a new, distinctive clinical entity. Jama Dermatol 151(3):316–319 PubMedCrossRef Gathings RM, Reddy R, Santa CD, Brodell RT (2015) Gadolinium-associated plaques: a new, distinctive clinical entity. Jama Dermatol 151(3):316–319 PubMedCrossRef
Metadaten
Titel
Gadoliniumablagerungen – Morbus Gadolinium
verfasst von
P. Raczeck
P. Fries
A. Bücker
G. Schneider
Publikationsdatum
08.04.2019
Verlag
Springer Medizin
Erschienen in
Die Radiologie / Ausgabe 5/2019
Print ISSN: 2731-7048
Elektronische ISSN: 2731-7056
DOI
https://doi.org/10.1007/s00117-019-0522-9

Weitere Artikel der Ausgabe 5/2019

Die Radiologie 5/2019 Zur Ausgabe

Einführung zum Thema

Kontrastprogramm

Informationstechnologie und Management

Was bringt die neue Strahlenschutzverordnung?

Mitteilungen des Berufsverbandes der Deutschen Radiologen

Mitteilungen des Berufsverbandes der Deutschen Radiologen

Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Radiologie und bleiben Sie gut informiert – ganz bequem per eMail.